Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersHematology & Oncology Physician in Boston, MA
NPI: 1306041975Primary Practice Location
MASSACHUSETTS GENERAL HOSPITAL
55 Fruit St, Boston, MA
Primary Employer
Massachusetts General Physicians Organization Inc
massgeneral.org
HQ Phone
Get M.D. Dejan's Phone Numberphone_androidMobile
Get M.D. Dejan's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMA State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 72 | 334 |
| 2 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 16 | 41 |
| 3 | 99223Initial hospital inpatient care, typically 70 minutes per day | 11 | 11 |
PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer.
Authors: Aditya Bardia, Leif Ellisen
Publication Date: 2018-07-23
Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer.
Authors: Aditya Bardia, Leif Ellisen, Steven Isakoff, Jennifer Aparicio, Jeffrey Peppercorn, Seth Wander, Irene Kuter, Laura Spring
Journal: Ther Adv Med Oncol
Publication Date: 2022-08-22
Authors: David Barch, James Cleary, Geoffrey Shapiro, Anthony Tolcher, Christopher Ocampo
Journal: Invest New Drugs
Publication Date: 2020-03-18
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Abemaciclib, DRUG: Fulvestrant, DRUG: Paclitaxel, DRUG: Imlunestrant, DRUG: LOXO-783, DRUG: Anastrozole, Exemestane, or Letrozole
Lead Sponsor: Cyteir Therapeutics, Inc.
Intervention / Treatment: DRUG: CYT-0851, DRUG: CYT-0851 in combination with gemcitabine, DRUG: CYT-0851 in combination with capecitabine, DRUG: CYT-0851 in combination with rituximab and bendamustine
Lead Sponsor: Vanderbilt-Ingram Cancer Center
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: laboratory biomarker analysis, DRUG: letrozole, DRUG: PI3K inhibitor BYL719, OTHER: pharmacological studies
